UBE2T

Ubiquitin-conjugating enzyme E2 T · Q9NPD8 · UBE2T on Sugi Atlas →

2,164 patent compounds predicted against UBE2T, 1,520 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7317820	0.77	2/20
SCHEMBL8324617	0.54	2/20
Hydrochloric Acid (SCHEMBL5916417)	0.53	2/20
Hydrochloric Acid (SCHEMBL8327897)	0.53	2/20
SCHEMBL415707	0.49	2/20
Hydrochloric Acid (SCHEMBL445078)	0.47	2/20
SCHEMBL8300549	0.46	2/20
SCHEMBL1924984	0.45	2/20
SCHEMBL3788282	0.45	2/20
Hydrochloric Acid (SCHEMBL3788110)	0.44	2/20
SCHEMBL1924156	0.41	2/20
SCHEMBL3781353	0.39	2/20
SCHEMBL244775	1.00	1/20
Hydrochloric Acid (SCHEMBL289191)	0.96	1/20
Hydrochloric Acid (SCHEMBL5009762)	0.96	1/20
SCHEMBL3529770	0.72	1/20
SCHEMBL226465	0.70	1/20
Hydrochloric Acid (SCHEMBL5010433)	0.69	1/20
Bromide (SCHEMBL7601035)	0.68	1/20
Water (SCHEMBL590685)	0.67	1/20

Clinical trials — most relevant to UBE2T by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	PHASE2/PHASE3	UNKNOWN
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults	PHASE3	WITHDRAWN
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Endocrine Disruptors and Life STILe in Breast Cancer Development	nan	UNKNOWN
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UBE2T binder may also engage these)

Protein	Name	Similarity
Q32LD2	—	1.000	Q32LD2 →
Q9CQ37	—	1.000	Q9CQ37 →
Q9CY34	—	0.999	Q9CY34 →
P63283	—	0.997	P63283 →
P63281	—	0.997	P63281 →
Q28CQ4	—	0.997	Q28CQ4 →
P63280	—	0.997	P63280 →
Q2EF73	—	0.997	Q2EF73 →
Q7ZY08	—	0.996	Q7ZY08 →
Q6NY82	—	0.995	Q6NY82 →
P40984	—	0.994	P40984 →
Q9D1C1	—	0.994	Q9D1C1 →
Q4R9D1	—	0.993	Q4R9D1 →
Q969M7	—	0.992	Q969M7 →
Q1RMW1	—	0.992	Q1RMW1 →
O00762	—	0.992	O00762 →
B4QHS6	—	0.992	B4QHS6 →
P21734	—	0.991	P21734 →
P52484	—	0.991	P52484 →
O74201	—	0.991	O74201 →
B0X6E8	—	0.991	B0X6E8 →
P52478	—	0.990	P52478 →
Q08BH7	—	0.990	Q08BH7 →
Q5M8Y2	—	0.990	Q5M8Y2 →
Q6DCZ9	—	0.990	Q6DCZ9 →
Q9SDY5	—	0.990	Q9SDY5 →
Q8L7T3	—	0.990	Q8L7T3 →
P52483	—	0.989	P52483 →
Q969T4	—	0.989	Q969T4 →
Q6BU36	—	0.989	Q6BU36 →